Who is sponsoring NCT05673434?

NCT05673434 is sponsored by Changhai Hospital.

What drugs are being tested in NCT05673434?

Interventions in NCT05673434: TM4SF1-positive chimeric antigen receptor T-cell therapy.

What condition does NCT05673434 study?

NCT05673434 studies Digestive Tumor.

Is NCT05673434 still recruiting?

NCT05673434 is currently status unknown. Last updated 6 January 2023.

Last reviewed 2023-01-06 · How we verify

NCT05673434

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1-positive Tumors of Digestive System

Status unknown NA Last updated 6 January 2023

What this trial tests

NA trial testing TM4SF1-positive chimeric antigen receptor T-cell therapy in Digestive Tumor in 24 participants. Status unknown.

Timeline

30 January 2023

Primary endpoint
30 July 2024

30 January 2025

Quick facts

Lead sponsor	Changhai Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	30 January 2023
Primary completion	30 July 2024
Estimated completion	30 January 2025

Drugs / interventions tested

TM4SF1-positive chimeric antigen receptor T-cell therapy — full drug profile →

Conditions studied

Digestive Tumor — all drugs for Digestive Tumor →

Sponsor

Changhai Hospital

Who can join

Adults 18 to 75, any sex, with Digestive Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Transmembrane 4 L Six Family Member 1 (TM4SF1) is highly expressed in many tumors of digestive system . The Chimeric Antigen Receptor T-cells (CAR-T) that target TM4SF1 has been generated in our good manufacturing practices (GMP) facility and the anti-tumor effects have been demonstrated in multiple in vitro and in vivo studies. Clinical studies are proposed here to evaluate the anti-tumor activity of these cell therapy products for treatment of patients with TM4SF1 positive tumors of digestive system. In this study, the safety, tolerance, and preliminary efficacy of CART-TM4SF1 cells will be examined in patients with refractory/recurrent advanced pancreatic cancer, colorectal cancer, gastric cancer or liver cancer. Clinical and immunological responses will be evaluated about 30 days and last up to 2 years after CAR-T cell infusion.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy in Gastrointestinal Cancers: Current Insights.
Jiang X, Zhan Y, Yang DH, Bao L. · · 2025 · cited 1× · PMID 40726819 · DOI 10.2147/cpaa.s497836
CAR-T cell therapy for pancreatic cancer: Translating emerging targets and dual-targeting strategies from solid tumors.
Shen S, Ruan Z, Jiang B, Qiu W, et al · · 2026 · PMID 42039159 · DOI 10.3389/fimmu.2026.1764452

Verify or expand the search:

Other Changhai Hospital trials

Trials by the same sponsor.

NCT07490002 — Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC · Phase 2 · not yet recruiting
NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
NCT07507071 — Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions · not yet recruiting
NCT07481591 — Capsule Endoscopy in GI Bleeding: A Retrospective Study · not yet recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05673434 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Changhai Hospital
Last refreshed: 6 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05673434.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing